TMO Q2 Deep Dive: Pharma Strength, Tariff Adaptation, and Strategic Investments Shape Outlook

Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 3% year on year to $10.86 billion. Its non-GAAP profit of $5.36 per share was 2.5% above analysts’ consensus estimates.

Is now the time to buy TMO? Find out in our full research report (it’s free).

StockStory’s Take

Thermo Fisher’s second quarter saw a positive market response, as the company surpassed Wall Street’s revenue and adjusted profit expectations. Management attributed the quarter’s performance to robust growth in pharma and biotech, especially in bioproduction and Pharma Services, alongside strong execution in their research and safety market channel. CEO Marc Casper emphasized that “customer uptake is very strong” for the company’s Accelerator Drug Development solution, and highlighted sequential improvement in clinical research. However, Casper also noted mid-single-digit declines in academic and government markets, and low single-digit declines in diagnostics and health care, reflecting ongoing hesitancy and demand headwinds in these segments.

Looking forward, Thermo Fisher’s updated guidance reflects an expectation of gradual improvement in key end markets and ongoing margin expansion through cost management and innovation. Management highlighted strategic priorities such as expanding U.S. manufacturing capacity, integrating Solventum’s Purification & Filtration business, and leveraging AI within their PPI Business System to enhance productivity. CFO Stephen Williamson noted, “We’re actively managing the company to appropriately navigate the macro environment,” while Casper outlined a scenario of accelerating growth in 2026 and 2027, anticipating organic revenue growth rising from current levels as academic and government headwinds abate and clinical research builds momentum.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to strong pharma and biotech demand, successful cost actions, and resilience in the face of tariffs, while also discussing product innovation and portfolio expansion.

• Pharma and Biotech Momentum: The company reported mid-single-digit growth in its pharma and biotech end markets, with bioproduction and Pharma Services driving results. Management cited strong customer interest in Accelerator Drug Development, which integrates Pharma Services and clinical research capabilities to reduce drug development time and cost.
• Academic and Government Weakness: Revenue from academic and government customers declined mid-single digits, with CEO Marc Casper pointing to muted demand and customer caution amid funding uncertainties. Casper indicated this segment is expected to stabilize over time but remains a headwind for now.
• Tariff Adaptation: Tariffs and related foreign exchange posed a significant headwind, impacting adjusted operating income and margins. Management minimized the impact through operational adjustments and active management, noting that tariff exposure was less severe than previously assumed, particularly in China.
• Product Innovation and Launches: Thermo Fisher introduced new mass spectrometry and electron microscopy products, including the Astral Zoom and Excedion Pro spectrometers and the Krios 5 cryo-transmission electron microscope. Customer feedback highlighted the potential of these tools to advance precision medicine and biological research.
• Portfolio and Capacity Expansion: The company amended its acquisition agreement with Solventum to accelerate regulatory clearance and exclude non-synergistic lines, while also announcing an expanded partnership with Sanofi through the acquisition of a sterile fill-finish facility in New Jersey. Management expects these moves to broaden manufacturing capabilities and support customer reshoring efforts.

Drivers of Future Performance

Thermo Fisher’s outlook centers on cost discipline, new product adoption, and recovery in challenged end markets, with ongoing tariff and policy risks.

• Cost Management and Margin Expansion: Management expects continued productivity gains and cost reductions, leveraging the PPI Business System and AI integration. CFO Stephen Williamson outlined expectations for 50 to 70 basis points of adjusted operating margin expansion annually, even in a muted revenue environment.
• Recovery in Key Markets: Leadership anticipates that academic and government demand will transition from a headwind to stabilization, while clinical research and pharma services are expected to see improved growth as authorizations and customer activity increase. China remains a near-term headwind but is projected to flatten out over the next two years.
• Strategic Capital Deployment: The company plans to supplement organic performance with targeted acquisitions and capacity investments, particularly in U.S. manufacturing. The pending Solventum and Sanofi deals are expected to enhance product offerings and meet growing demand for domestic drug production, supporting long-term revenue and profit growth.

Catalysts in Upcoming Quarters

In the quarters ahead, our analyst team will closely watch (1) the pace of recovery in academic and government demand and whether stabilization emerges, (2) the successful integration and performance of Solventum’s Purification & Filtration business and the Sanofi fill-finish facility, and (3) ongoing traction for new analytical instruments and bioproduction solutions. Execution on cost discipline and navigating tariff dynamics will also be key signposts for monitoring Thermo Fisher’s ability to deliver on its outlook.

Thermo Fisher currently trades at $467.60, up from $426.83 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.